This brand name is authorized in Brazil
The drug VENDEXLA contains one active pharmaceutical ingredient (API):
|
1
Desvenlafaxine
UNII ZB22ENF0XR - DESVENLAFAXINE SUCCINATE
|
|
Desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI), indicated for the treatment of major depressive disorder [MDD]. The clinical efficacy of desvenlafaxine is thought to be related to the potentiation of these neurotransmitters in the central nervous system. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06AX23 | Desvenlafaxine | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 543518090009204, 543518090009304, 543518090009404, 543518090009504 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
